Oculis climbs on positive mid-stage trial for eye treatment

Oculis Holding AG

06/01/2025 12:53

** U.S.-listed shares of Switzerland-based drug developer
Oculis Holding  CR5.F   OCS.O  rise 6.8% to $18.75 premarket
    ** Co says its drug, OCS-05, met the main goal of safety in
a mid-stage trial testing it in patients with acute optic
neuritis, an inflammatory condition that causes sudden vision
loss
    ** Says the drug also improved patients' visual function
during the trial
    ** Up to last close, stock up 66.3% in the last 12 months

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))